Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has issued an update.
Q-linea reported full-year 2025 net sales of SEK 11.1 million, up from SEK 2.4 million a year earlier, while narrowing its operating loss to SEK 176.7 million and strengthening its balance sheet with a nearly fully subscribed rights issue that raised about SEK 312 million. The company expanded its installed base of ASTar systems to 19 contracted instruments, with Italy emerging as a key reference market and the United States entering a commercial phase marked by the first hospital contracts, conversions from competitor platforms, and building demand ahead of an expanded ASTar test menu expected to launch in 2026. Management implemented a cost-reduction program, shifted resources from development to commercial roles, brought consumables production in-house to improve margins, and restructured the organization under a new CEO, all aimed at driving consumables-led recurring revenues, supporting global expansion and positioning Q-linea to reach breakeven by 2027.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish diagnostics company specializing in rapid antimicrobial susceptibility testing (AST) through its ASTar platform, targeting hospitals and healthcare systems that need faster, more reliable tools to combat antimicrobial resistance and improve sepsis and infection management worldwide.
Average Trading Volume: 15,235
Technical Sentiment Signal: Sell
Current Market Cap: SEK521.3M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.